供者来源CD7 CAR-T治疗复发难治T-ALL首次人体I期试验
该单中心I期试验纳入20例复发难治T细胞急性淋巴细胞白血病患者,输注供者来源抗CD7 CAR-T细胞,剂量为5×10^5或1×10^6(±30%)细胞/千克体重。90%患者达完全缓解,安全性总体可控,主要不良事件为可逆性细胞因子释放综合征和血细胞减少。
要点
- 供者CD7 CAR-T在r/r T-ALL中完全缓解率达90%(18/20)。
- 3-4级细胞因子释放综合征发生率10%,3-4级血细胞减少100%。
- 1-2级移植物抗宿主病发生率60%,均为可逆。
核心结论
- 供者来源CD7 CAR-T细胞在20例r/r T-ALL中高效扩增并获高完全缓解率,安全性可控。
研究设计与样本
- 单中心I期试验,20例r/r T-ALL接受供者来源抗CD7 CAR-T单次输注,剂量5×10^5或1×10^6(±30%)细胞/千克体重,主要终点为安全性。
主要发现
- 1-2级细胞因子释放综合征发生率90%(n=18),3-4级10%(n=2)。
- 3-4级血细胞减少发生率100%(n=20),1-2级神经毒性15%(n=3)。
- 1-2级移植物抗宿主病发生率60%(n=12),1-2级病毒激活20%(n=4)。
- 90%(n=18)达完全缓解,7例后续桥接干细胞移植;中位随访6.3个月(范围4.0-9.2),15例维持缓解。
- 输注后6个月评估的5例中5例仍可检测到CAR-T细胞;CD7阴性T细胞扩增可能减轻T细胞免疫缺陷。
关键数值与推荐
- 完全缓解率90%(18/20),中位随访6.3个月时15例仍缓解。
- 不良事件除1例输注后5.5个月因真菌肺炎相关肺出血死亡外均逆转。
临床怎么用
- 供者CD7 CAR-T可作为r/r T-ALL的高缓解率桥接方案,需监测细胞因子释放综合征、血细胞减少和移植物抗宿主病。
局限性
- 单中心I期试验,样本量20例,随访时间短(中位6.3个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell safety and efficacy in patients with r/r T-ALL. METHODS: In this single-center, phase I trial, we administered anti-CD7 CAR T cells, manufactured from either previous stem-cell transplantation donors or new donors, to patients with r/r T-ALL, in single infusions at doses of 5 × 105 or 1 × 106 (±30%) cells per kilogram of body weight. The primary end point was safety with efficacy secondary. RESULTS: Twenty participants received infusions. Adverse events including cytokine release syndrome grade 1-2 occurred in 90% (n = 18) and grade 3-4 in 10% (n = 2), cytopenia grade 3-4 in 100% (n = 20), neurotoxicity grade 1-2 in 15% (n = 3), graft-versus-host disease grade 1-2 in 60% (n = 12), and viral activation grade 1-2 in 20% (n = 4). All adverse events were reversible, except in one patient who died through pulmonary hemorrhage related to fungal pneumonia, which occurred at 5.5 months, postinfusion. Ninety percent (n = 18) achieved complete remission with seven patients proceeding to stem-cell transplantation. At a median follow-up of 6.3 months (range, 4.0-9.2), 15 remained in remission. CAR T cells were still detectable in five of five patients assessed in month 6, postinfusion. Although patients' CD7-positive normal T cells were depleted, CD7-negative T cells expanded and likely alleviated treatment-related T-cell immunodeficiency. CONCLUSION: Among 20 patients with r/r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile. A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659).
引用
- Pan J, Tan Y, Wang G, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021. PMID: 34324392. doi:10.1200/JCO.21.00389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。